COUNTERFEIT VIAGRA

Last September Polish police raided a factory in Bydgoszcz and found 100,000 fake Viagra pills and 43,000 vials of steroids. Counterfeit drugs have found a new dealer and it was in shady internet “pharmacies” selling erectile dysfunction drugs to desperate buyers around the globe. No prescription needed, no medical questions to answer, no physician review.

The sale and purchase of medications is illegal and supports some of the worst criminals who enrich themselves by preying on people’s needs. Equally bad, patients often receive inferior and contaminated medications made in unsanitary conditions.

Read more

Cialis vs. Sildenafil

A brief comparison of Sildenafil (Viagra) with Tadalafil (Cialis) can be made by examining how they can be used (daily versus ‘as needed’), the time it takes for them to work, the length of time they continue to work, the restrictions on how they can be taken, the contraindications to their use, and the side effects each of them might cause. Read more

Levitra vs. Viagra

Weighing the benefits and risks of both Viagra and Levitra requires some basic knowledge of each. A comparison can be made by examining how they can be used, the time it takes for them to work, the length of time they work, the restrictions on how they can be taken, the contraindications to their use, and their side effects. Read more

Generic Cialis

In July 2017, Eli Lilly announced that Cialis (Tadalafil) would not be coming off patent protection in November of this year, as was expected. They arrived at a new patent settlement with multiple generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple, pharmaceutical companies and there should be some downward pressure on price due to the competition. Read more

Cialis Over-the-Counter

In May 2014, Sanofi, the French pharmaceutical company acquired the exclusive rights to apply for the rights to market Cialis over-the-counter (OTC) from drug company Lilly. When off patent, Sanofi has the right to make all applications for over-the-counter (OTC) approval in the United States, Australia, Canada, and Europe. Read more

Cialis patent expiration

In July 2017, Eli Lilly announced that Cialis (generic name Tadalafil) would not be coming off patent protection in November of this year as was expected. They arrived at a new patent settlement with multiple generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition. Read more

Generic erectile dysfunction medication

Read more about generic ED meds or get started with an online consultation. Viagra’s patent protection ends in 2020. However, in an agreement with Teva pharmaceuticals, a generic will be available in December of this year. Only a single pharmaceutical company will make generic Viagra, called Sildenafil, so the pressure from competition will not be a factor driving down prices. Viagra created income for Pfizer of more than 1.5 billion dollars in 2016. In a related matter, Eli Lilly announced in July 2017, that Cialis would not come off patent protection in November of this year, as was expected. They arrived at a new, patent settlement with multiple, generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition–as opposed to the situation with Viagra.

First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.

In 2016, Cialis netted Lilly nearly 1.5 billion dollars. The patent for Levitra (Vardenafil) does not expire until October 31, 2018. Sales for the maker of Levitra were about 250 million dollars in 2015. It is interesting that this is approximately the time when both Cialis (Tadalafil) and Viagra (Sildenafil) will have generic versions available. The price of Levitra generic will probably drop as many other drugs treating erectile dysfunction will be available as a generic.

More ED Drugs on Roman


Read more from our Medical Guides.

Generic Levitra

The patent for Levitra (Vardenafil) does not expire until October 31, 2018. Sales for the maker of Levitra were about 250 million dollars in 2015. It is interesting that this is approximately the time when both Cialis (Tadalafil) and Viagra (Sildenafil) will have generic versions available.

Viagra’s patent protection ends in 2020. However, in an agreement with Teva pharmaceuticals, a generic will be available in December of this year. Only a single pharmaceutical company will make generic Viagra, called Sildenafil, so the pressure from competition will not be a factor driving down prices.

Viagra created income for Pfizer of more than 1.5 billion dollars in 2016.

In a related matter, Eli Lilly announced in July 2017, that Cialis would not come off patent protection in November of this year, as was expected. They arrived at a new, patent settlement with multiple, generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition–as opposed to the situation with Viagra.

First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.

In 2016, Cialis netted Lilly nearly 1.5 billion dollars.

The price of Levitra generic will probably drop as many other drugs treating erectile dysfunction will be available as a generic at the same time.

Levitra Over-the-Counter

There are no plans noted by Bayer to make application to market Levitra as an over-the-counter (OTC) drug.

However, in May 2014, Sanofi, the French pharmaceutical company acquired the exclusive rights to apply for the rights to market Cialis over-the-counter from drug company Lilly. When off patent, Sanofi has the right to make all applications for OTC approval in the United States, Australia, Canada, and Europe.

That said, the hurdles would be enormous in the United States. Even in Europe it proved to be a difficult challenge for Pfizer back in 2008 when they sought to gain approval for OTC sales of Viagra. Concerns about the potential for misuse, the complicated educational material needed to accompany the medication, and the fact that the underlying medical conditions leading to ED would go untreated, left the company no choice but to withdraw its request.

At the moment no plans exist for Viagra to go over-the-counter but the Sanofi deal with Lilly remains and with Cialis beginning to lose its multiple patent protections, it is possible that Sanofi will explore the potential for Cialis to go OTC. Nevertheless, the concerns have only increased about allowing underlying conditions to remain untreated, and for an opportunity to educate men about the need to utilize the healthcare system to go unmet. There is an appreciation for the need for education and the benefit of coaxing men into their doctor’s office for evaluation.

For the foreseeable future, it is hard to imagine any of the erectile dysfunction drugs becoming available over-the-counter.

Generic Viagra

The patent protection on Viagra ends in 2020. However, in an agreement with Teva pharmaceuticals, a generic will be available in December of this year. Only a single pharmaceutical company will make generic Viagra, called Sildenafil, so the pressure from competition will not be a factor driving down prices.

Viagra created income for Pfizer of more than 1.5 billion dollars in 2016.

In a related matter, Eli Lilly announced in July 2017, that Cialis would not come off patent protection in November of this year, as was expected. They arrived at a new, patent settlement with multiple, generic pharmaceutical companies that extended Lilly’s protection of Cialis until September 27, 2018. The agreement was reached with multiple pharmaceutical companies and there should be some downward pressure on price due to the competition–as opposed to the situation with Viagra.

First approved in 2003, it has been a major source of income creating 17 billion dollars of income for Lilly.

In 2016, Cialis netted Lilly nearly 1.5 billion dollars.